Cancer Research Annual Meeting 2010  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 3164-3173, June 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belinsky, S. A.
Right arrow Articles by Anderson, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belinsky, S. A.
Right arrow Articles by Anderson, M. W.

Role of the Alveor Type II Cell in the Development and Progression of Pulmonary Tumors Induced bt 4-(Methylnitrosamino)-(3-pyridyl)-1-butanone in the A/J Mouse

Steven A. Belinsky1, Theodora R. Devereux, Julie F. Foley, Robert R. Maronpot and Marshall W. Anderson2

Laboratory of Molecular Toxicology [S. A. B., T. R. D., M. W. A.] and National Toxicology Program [J. F. F., R. R. M.], National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709

The role of the type II cell in the development of pulmonary tumors induced in the adult A/J mouse (6 weeks of age) by treatment with a single dose (100 mg/kg, i.p.) of 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone (NNK) was investigated. Twenty-four h following treatment with NNK, the concentration of O6-methylguanine was similar in Clara and type II cells. However, hyperplasias were detected only along the alveolar septa in lungs 14 weeks after carcinogen treatment. Examination of the ultrastructure of several hyperplasias revealed that the proliferating cells resembled type II pneumocytes. The proliferating cells were cuboidal in shape, with centrally localized ovoid nuclei characterized by minor indentations. Lamellar bodies, one of the major hallmarks of the type II cell, were present in the cytoplasm. The progression of pulmonary lesions was followed by sacrificing mice at 4-week intervals from 14 to 54 weeks after treatment with NNK. From 34 to 42 weeks after treatment, progression to neoplasia was demonstrated by a decline in the frequency of hyperplasias and an increase in the frequency of adenomas. Approximately 50% of the adenomas were observed arising within hyperplasias. Carcinomas appeared to increase in frequency 34 weeks after carcinogen treatment and comprised greater than 50% of the pulmonary lesions by 54 weeks. Approximately 30% of the carcinomas were observed arising within adenomas. The growth pattern of carcinomas began to change from solid to mixed (solid and papillary) 42 weeks after NNK. Moreover, electron micrographie analysis demonstrated that, within a hyperplasia, proliferating type II cells could change from cuboidal to columnar in shape and could also exhibit nuclear indentations, both characteristics displayed by the Clara cell. Thus, this divergence of the type II cell from its well characterized morphological features indicates that the selective growth advantage which these initiated cells possess can result in changes to the normal ultrastructure of this cell as it progresses toward malignancy. DNA was isolated from 20 hyperplasias and screened for the presence of an activated K-ras gene. This gene was activated in 17 of 20 lesions, with 85% of the mutations involving a GC to AT transition within codon 12 (GGT to GAT), a mutation consistent with base mispairing produced by the formation of the O6-methylguanine adduct. This specificity for activation of the K-ras gene was identical to that observed previously in adenocarcinomas induced by NNK. These results indicate that the genesis of pulmonary neoplasia induced in the A/J mouse by NNK involves formation of the O6-methylguanine adduct within type II cells, which leads to the activation of the K-ras gene, followed by proliferation of type II cells and subsequent progression to a malignant tumor.

1 Present address: Molecular and Cellular Toxicology Group, Inhalation Toxicology Research Institute, PO Box 5890, Albuquerque, NM 87185.

2 To whom requests for reprints should be addressed.




This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Y. Kim, L. Von Weymarn, O. Larsson, D. Fan, J. M. Underwood, M. S. Peterson, S. S. Hecht, V. A. Polunovsky, and P. B. Bitterman
Eukaryotic Initiation Factor 4E Binding Protein Family of Proteins: Sentinels at a Translational Control Checkpoint in Lung Tumor Defense
Cancer Res., November 1, 2009; 69(21): 8455 - 8462.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. D.F. Licchesi, W. H. Westra, C. M. Hooker, E. O. Machida, S. B. Baylin, and J. G. Herman
Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung
Carcinogenesis, May 1, 2008; 29(5): 895 - 904.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
Q. Tao, J. Fujimoto, T. Men, X. Ye, J. Deng, L. Lacroix, J. L. Clifford, L. Mao, C. S. Van Pelt, J. J. Lee, et al.
Identification of the Retinoic Acid Inducible Gprc5a As a New Lung Tumor Suppressor Gene
J Natl Cancer Inst, November 21, 2007; 99(22): 1668 - 1682.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding
Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice
Cancer Res., August 15, 2007; 67(16): 7825 - 7832.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
N. Wakamatsu, T. R. devereux, H.-H. L. Hong, and R. C. Sills
Overview of the Molecular Carcinogenesis of Mouse Lung Tumor Models of Human Lung Cancer
Toxicol Pathol, January 1, 2007; 35(1): 75 - 80.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. Razani-Boroujerdi and M. L. Sopori
Early Manifestations of NNK-Induced Lung Cancer: Role of Lung Immunity in Tumor Susceptibility
Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 13 - 19.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
B. R. Vuillemenot, J. A. Hutt, and S. A. Belinsky
Gene Promoter Hypermethylation in Mouse Lung Tumors
Mol. Cancer Res., April 1, 2006; 4(4): 267 - 273.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. A. Hutt, B. R. Vuillemenot, E. B. Barr, M. J. Grimes, F. F. Hahn, C. H. Hobbs, T. H. March, A. P. Gigliotti, S. K. Seilkop, G. L. Finch, et al.
Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways
Carcinogenesis, November 1, 2005; 26(11): 1999 - 2009.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. A. Belinsky
Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer
Carcinogenesis, September 1, 2005; 26(9): 1481 - 1487.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. K. Bauer, A. M. Malkinson, and S. R. Kleeberger
Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities
Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L685 - L703.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. C. Pulling, B. R. Vuillemenot, J. A. Hutt, T. R. Devereux, and S. A. Belinsky
Aberrant Promoter Hypermethylation of the Death-Associated Protein Kinase Gene Is Early and Frequent in Murine Lung Tumors Induced by Cigarette Smoke and Tobacco Carcinogens
Cancer Res., June 1, 2004; 64(11): 3844 - 3848.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. R. Vuillemenot, L. C. Pulling, W. A. Palmisano, J. A. Hutt, and S. A. Belinsky
Carcinogen exposure differentially modulates RAR-{beta} promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis
Carcinogenesis, April 1, 2004; 25(4): 623 - 629.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Takeuchi, K. Saoo, M. Yokohira, M. Ikeda, H. Maeta, M. Miyazaki, H. Yamazaki, T. Kamataki, and K. Imaida
Pretreatment with 8-Methoxypsoralen, a Potent Human CYP2A6 Inhibitor, Strongly Inhibits Lung Tumorigenesis Induced by 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Female A/J Mice
Cancer Res., November 15, 2003; 63(22): 7581 - 7583.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. A. Belinsky, D. M. Klinge, C. A. Stidley, J.-P. Issa, J. G. Herman, T. H. March, and S. B. Baylin
Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer
Cancer Res., November 1, 2003; 63(21): 7089 - 7093.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. Tesfaigzi, P. S. Wright, and S. A. Belinsky
SPRR1B overexpression enhances entry of cells into the G0 phase of the cell cycle
Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L889 - L898.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. R. Devereux, W. Holliday, C. Anna, N. Ress, J. Roycroft, and R. C. Sills
Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years
Carcinogenesis, October 1, 2002; 23(10): 1737 - 1743.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. A. Wardlaw, N. Zhang, and S. A. Belinsky
Transcriptional Regulation of Basal Cyclooxygenase-2 Expression in Murine Lung Tumor-Derived Cell Lines by CCAAT/Enhancer-Binding Protein and Activating Transcription Factor/cAMP Response Element-Binding Protein
Mol. Pharmacol., August 1, 2002; 62(2): 326 - 333.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
L.C.H. John
The effect of subcutaneous tumour implantation in a murine lung tumour model
Eur. J. Cardiothorac. Surg., April 1, 2002; 21(4): 616 - 620.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
T. H. March, P. G. Marron-Terada, and S. A. Belinsky
Refinement of an Orthotopic Lung Cancer Model in the Nude Rat
Vet. Pathol., September 1, 2001; 38(5): 483 - 490.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. R. Dahl, I. M. Grossi, D. P. Houchens, L. J. Scovell, M. E. Placke, A. R. Imondi, G. D. Stoner, L. M. De Luca, D. Wang, and J. L. Mulshine
Inhaled Isotretinoin (13-cis Retinoic Acid) Is an Effective Lung Cancer Chemopreventive Agent in A/J Mice at Low doses: A Pilot Study
Clin. Cancer Res., August 1, 2000; 6(8): 3015 - 3024.
[Abstract] [Full Text]


Home page
Toxicol PatholHome page
H.-H. L. Hong, T. R. Devereux, R. L. Melnick, C. R. Moomaw, G. A. Boorman, and R. C. Sills
Mutations of ras Protooncogenes and p53 Tumor Suppressor Gene in Cardiac Hemangiosarcomas from B6C3F1 Mice Exposed to 1,3-Butadiene for 2 Years
Toxicol Pathol, July 1, 2000; 28(4): 529 - 534.
[Abstract] [PDF]


Home page
CarcinogenesisHome page
S. A. Wardlaw, T. H. March, and S. A. Belinsky
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions
Carcinogenesis, July 1, 2000; 21(7): 1371 - 1377.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. B.J. Smith, A. Castonguay, P. J. Donnelly, K. R. Reid, D. Petsikas, and T. E. Massey
Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells
Carcinogenesis, September 1, 1999; 20(9): 1809 - 1818.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. Liu, X. Qin, and S. L. Gerson
Reduced lung tumorigenesis in human methylguanine DNA—methyltransferase transgenic mice achieved by expression of transgene within the target cell
Carcinogenesis, February 1, 1999; 20(2): 279 - 284.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.